Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bermekimab (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms GENESIS
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 30 Aug 2024 Results published in the Archives of Dermatological Research
    • 20 Apr 2022 This trial has been completed in Germany (End Date: 31 March 2022) according to European Clinical Trials Database record.
    • 15 Apr 2022 This trial was completed in Germany (global end date: 2022-03-31), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top